First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.
Fiche du document
- doi: 10.1111/ajt.16062
- issn: 1600-6135
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/ajt.16062
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32412159
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1600-6143
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_62886B3772255
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Infectious diseasesCiter ce document
J. Tschopp et al., « First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. », Serveur académique Lausannois, ID : 10.1111/ajt.16062
Métriques
Partage / Export
Résumé
Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%), and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.